IMAPAC Glossary

Knowledge Management refers to systematic processes capturing, organising, sharing, and applying organisational knowledge to improve efficiency, decision-making, and innovation. This includes managing scientific data, manufacturing records, regulatory documentation, and lessons learned across programmes and product lifecycles. Effective knowledge management reduces duplication, prevents errors, and supports consistent execution across teams and sites.

The biopharmaceutical industry applies knowledge management to strengthen compliance and accelerate development. Regulatory submissions require structured documentation and traceability, making knowledge systems critical for inspection readiness and lifecycle management. Manufacturing benefits through standardised procedures, deviation learning, and technology transfer continuity. Research teams use knowledge platforms to track experimental outcomes, enable collaboration, and preserve institutional memory. As digital transformation expands, knowledge management increasingly integrates with electronic lab notebooks, quality management systems, and data platforms enabling more efficient and compliant operations across global organisations.

Label Expansion refers to the regulatory approval of additional indications, patient populations, dosing regimens, combinations, or routes of administration for a therapy already authorised for clinical use. It represents a structured pathway for broadening the scope of an existing product label based on new clinical evidence, typically supported by additional Phase II or III trials, real-world evidence, or post-marketing commitments. Label expansion may include moving a drug into earlier lines of therapy, expanding from adult to paediatric populations, adding new biomarkers, or demonstrating benefit in a related disease area.

The biopharmaceutical industry pursues label expansion as a major strategy for maximising therapeutic impact and sustaining product value over time. Expansion programmes require robust clinical trial design, careful endpoint selection, and strong benefit-risk justification, particularly when new patient groups present different safety considerations. Regulatory submissions often include updated safety databases, subgroup analyses, and additional manufacturing or pharmacovigilance commitments. From a commercial and access perspective, label expansion can significantly increase eligible patient populations, strengthen reimbursement positioning, and improve treatment adoption through updated clinical guidelines. As precision medicine grows, label expansions increasingly depend on biomarker-driven evidence, requiring integrated companion diagnostics and aligned regulatory strategies across regions.

Laboratory Developed Test (LDT) designates a diagnostic assay designed, manufactured, validated, and used within a single laboratory, often to address specialised clinical questions where commercial diagnostic kits are unavailable or insufficient. LDTs may detect genetic mutations, measure protein biomarkers, assess infectious disease targets, or evaluate complex multi-analyte signatures used in personalised medicine. These tests are typically implemented in high-complexity laboratories with established quality systems.

The pharmaceutical and biopharmaceutical industry engages with LDTs extensively during biomarker discovery, clinical trial enrolment, and translational research programmes. In early development, LDTs may serve as the first practical diagnostic tool to identify responsive patient subgroups, especially when companion diagnostics are not yet commercially available. LDT performance requires strong analytical validation, including accuracy, precision, sensitivity, specificity, and reproducibility across sample types and instruments. Regulatory expectations around LDT oversight continue evolving, making compliance and documentation increasingly critical for clinical trial credibility and downstream regulatory submissions. As targeted therapies expand, LDTs remain essential in bridging scientific discovery with real-world clinical implementation.

Lactate Dehydrogenase (LDH) is an enzyme involved in cellular energy metabolism, catalysing the interconversion of lactate and pyruvate during glycolysis and oxidative pathways. LDH is widely present across tissues, and elevated LDH levels in blood often reflect tissue damage, inflammation, hypoxia, or high cellular turnover. In oncology and infectious diseases, LDH can serve as a non-specific biomarker of disease burden, tumour aggressiveness, or systemic physiological stress.

The pharmaceutical industry uses LDH as both a safety marker and a disease-related biomarker across clinical development programmes. In cancer trials, LDH may correlate with prognosis and may be included as a baseline stratification factor or exploratory endpoint. In cell therapy and immunotherapy development, LDH release assays are frequently used in vitro to assess cytotoxicity, immune-mediated killing, and cell membrane integrity. Elevated LDH in patients may signal treatment-related toxicities, tumour lysis, or broader inflammatory responses, requiring careful clinical interpretation. Because LDH is not disease-specific, it is most valuable when analysed alongside clinical symptoms, imaging findings, and additional biomarkers, supporting integrated assessment of therapeutic response and safety.

Latent Viral Reservoir refers to populations of infected cells that harbour viral genetic material in a dormant or transcriptionally silent state, enabling viruses to persist despite immune clearance and antiviral therapy. This concept is most clinically significant in chronic viral infections such as HIV, where latent reservoirs remain the primary barrier to cure. These reservoirs can reactivate under certain conditions, leading to viral rebound if therapy is stopped.

The biopharmaceutical industry targets latent viral reservoirs through advanced therapeutic strategies aimed at achieving functional cure or eradication. Approaches include latency-reversing agents that reactivate dormant virus for immune clearance, immune-based therapies enhancing cytotoxic responses, broadly neutralising antibodies, and gene editing technologies that disrupt viral DNA or host entry pathways. Clinical development is challenging due to the need for sensitive assays to quantify reservoir size, the complexity of tissue compartmentalisation, and ethical constraints of treatment interruption studies. Regulatory pathways require strong safety justification because interventions may involve immune activation or genetic modification. As antiviral innovation advances, latent reservoir research continues shaping next-generation curative strategies and long-term disease control frameworks.

Lead Compound denotes a chemical or biological molecule demonstrating desirable biological activity against a validated target and possessing sufficient properties to justify further optimisation in drug discovery. It represents the transition point between screening hits and drug candidate development, where promising activity must be accompanied by tractable chemistry and acceptable early safety signals.

The pharmaceutical industry identifies lead compounds through high-throughput screening, structure-based design, fragment screening, or in silico modelling. Lead optimisation refines potency, selectivity, stability, solubility, and safety through systematic chemical modification. Multiple lead series may progress in parallel before selecting a development candidate. Evaluation includes in vitro activity, preliminary pharmacokinetics, toxicity signals, and synthetic feasibility. A strong lead balances biological efficacy with drug-like characteristics enabling progression towards clinical viability. Many leads ultimately fail due to safety, metabolism, or formulation challenges, highlighting the importance of early comprehensive profiling. The lead compound stage transforms scientific discovery into structured development, defining the chemical foundation upon which future therapeutics are built.

Lead Identification describes the stage of drug discovery where initial active molecules are selected as promising starting points for further optimisation. These leads typically emerge from high-throughput screening, fragment-based discovery, structure-based design, phenotypic screening, or computational approaches, and they demonstrate measurable activity against a validated biological target. Lead identification goes beyond simply finding hits by prioritising compounds with favourable early properties including tractable chemistry, preliminary selectivity, and acceptable safety signals.

The pharmaceutical industry invests heavily in lead identification because early decisions strongly influence development success and attrition risk. Leads are evaluated through integrated profiling including potency assays, counter-screening against related targets, solubility assessment, metabolic stability testing, and early toxicity flagging. Multiple lead series may be developed in parallel to reduce dependency on a single chemical scaffold. Advanced workflows incorporate medicinal chemistry feasibility, intellectual property considerations, and early manufacturability planning. Lead identification transforms scientific observations into development-ready programmes, establishing the foundation for later optimisation steps that ultimately determine whether a molecule can become a clinically viable drug candidate.

Lead Optimisation refers to the systematic process of improving the properties of a lead compound through iterative chemical modification and biological testing, with the goal of producing a development candidate suitable for clinical evaluation. This stage focuses on enhancing potency, selectivity, pharmacokinetics, safety margins, and physicochemical properties such as solubility and stability. Lead optimisation integrates structure-activity relationship analysis, mechanistic understanding, and experimental validation.

The pharmaceutical industry approaches lead optimisation as a multidisciplinary effort involving medicinal chemists, pharmacologists, toxicologists, formulation scientists, and computational teams. Candidate molecules are refined through repeated design-make-test cycles, supported by in vitro assays and in vivo studies evaluating absorption, distribution, metabolism, and elimination. Safety assessment includes screening for off-target interactions, genotoxicity risks, cardiac ion channel inhibition, and reactive metabolite formation. Optimisation may also address route of administration goals, such as improving oral bioavailability or enabling once-daily dosing. Regulatory expectations for candidate selection require strong data packages demonstrating robust activity, acceptable safety signals, and reproducible synthesis routes, making lead optimisation one of the most critical phases in transforming a promising molecule into a realistic therapeutic candidate.

Lentiviral Vector refers to a gene delivery system derived from lentiviruses, engineered to safely introduce genetic material into target cells while removing pathogenic replication capability. Lentiviral vectors are capable of transducing both dividing and non-dividing cells, enabling stable gene integration and long-term expression. This makes them particularly valuable in ex vivo gene therapy and cell therapy manufacturing, where durable modification of patient-derived cells is required.

The biopharmaceutical industry relies on lentiviral vectors as a core enabling technology for CAR-T cell therapies and other genetically engineered cell products. Manufacturing involves stringent quality control testing for vector titre, purity, residual host cell DNA, replication-competent lentivirus, and genetic integrity. Regulatory scrutiny is high due to insertional mutagenesis risks, requiring comprehensive safety evaluation and long-term patient monitoring in clinical trials. Scale-up challenges include maintaining consistent yield, ensuring batch reproducibility, and securing sufficient manufacturing capacity as clinical demand rises. As advanced therapies expand globally, lentiviral vector innovation continues through improved production platforms, safer designs, and more efficient transduction processes.

Lentivirus refers to a subclass of retroviruses capable of integrating genetic material into both dividing and non-dividing cells, enabling stable, long-term gene expression. Modified lentiviral vectors are widely used in gene therapy, cell therapy, and molecular biology research due to their efficient gene delivery capabilities and ability to provide durable transgene expression following integration into the host genome.

The biopharmaceutical industry employs lentiviral vectors extensively for CAR-T cell manufacturing, gene replacement therapies, and functional genomics. These vectors deliver therapeutic genes into patient cells ex vivo or directly into tissues in vivo. Lentiviral systems are engineered to remove pathogenic components while retaining delivery efficiency. Manufacturing involves strict quality control addressing vector titre, purity, replication competence, and genetic integrity. Regulatory scrutiny is high due to integration risks, requiring comprehensive safety assessments and long-term patient monitoring. Lentiviral vectors remain essential tools enabling durable gene expression, cellular engineering, and personalised therapies, particularly in oncology and rare genetic diseases.

Ligand designates a molecule that binds specifically to a biological target such as a receptor, enzyme, ion channel, or protein complex, influencing its function through activation, inhibition, or modulation. Ligands may be endogenous molecules naturally present in the body, such as hormones and neurotransmitters, or synthetic compounds designed for therapeutic intervention. Ligand binding is governed by molecular recognition, affinity, kinetics, and conformational compatibility, determining downstream biological responses.

In drug discovery and development, ligands represent the fundamental basis of therapeutic design because target engagement drives both efficacy and safety. Ligands may function as agonists, antagonists, partial agonists, inverse agonists, or allosteric modulators depending on how they alter receptor signalling. Structure-activity relationship studies refine ligand properties by optimising potency, selectivity, metabolic stability, and tissue distribution. Ligands are also used as diagnostic probes, imaging agents, and assay reagents supporting target validation and mechanistic research. Understanding ligand behaviour under physiological conditions is essential for predicting clinical response, designing dosing strategies, and minimising off-target effects, making ligand science central to modern pharmacology and therapeutic innovation.

Ligand Binding Assay refers to analytical methods that quantify the interaction between a ligand and its biological target, enabling measurement of binding affinity, kinetics, specificity, and receptor occupancy. These assays may involve labelled or label-free formats and are used to characterise molecular recognition events essential for drug discovery. Common approaches include radioligand binding assays, fluorescence polarisation, surface plasmon resonance, bio-layer interferometry, and immunoassays depending on target type and information requirements.

The pharmaceutical industry uses ligand binding assays extensively across lead identification, lead optimisation, and regulatory documentation. Competitive binding assays assess whether a candidate compound can displace a known ligand, supporting potency ranking and selectivity profiling. Saturation binding assays provide key parameters such as dissociation constants and receptor density. For biologics, ligand binding assays may measure antibody binding to antigens or biomarker levels in clinical samples. Assay development requires careful optimisation to minimise non-specific binding, matrix interference, and signal variability, with validation demonstrating accuracy, precision, sensitivity, and robustness. As therapeutic modalities expand into complex targets and multispecific formats, ligand binding assays remain essential tools translating molecular interactions into quantitative evidence.

Lipase is an enzyme that catalyses the breakdown of triglycerides into free fatty acids and glycerol, playing a central role in lipid digestion, absorption, and metabolic regulation. Lipases exist in multiple forms across biological systems, including pancreatic lipase involved in dietary fat digestion, hepatic lipase contributing to lipoprotein metabolism, and lipoprotein lipase regulating fatty acid uptake in tissues. Beyond digestion, lipases participate in signalling pathways and energy balance, making them important in metabolic health and disease.

The pharmaceutical and biotechnology industry applies lipase knowledge across diagnostics, therapeutic development, and industrial biocatalysis. Clinically, serum lipase testing supports diagnosis of pancreatic injury and pancreatitis. Therapeutically, lipase inhibition has been explored in obesity management through reducing dietary fat absorption. In manufacturing and green chemistry, lipases are valuable biocatalysts enabling stereoselective synthesis, esterification, and transesterification reactions under mild conditions, improving sustainability compared to traditional chemical processes. Advances in protein engineering and immobilisation techniques improve lipase stability and performance, expanding applications across pharmaceutical synthesis, food technology, and industrial biotechnology.

Lipid Nanoparticle (LNP) refers to nanoscale lipid-based delivery systems designed to encapsulate and protect nucleic acid therapeutics such as mRNA, siRNA, or gene editing components, enabling efficient delivery into target cells. LNPs typically contain ionisable lipids, helper lipids, cholesterol, and polyethylene glycol lipids that collectively support stability, cellular uptake, endosomal escape, and controlled biodistribution. This platform gained major prominence through mRNA vaccine development and has since expanded into multiple therapeutic areas.

The biopharmaceutical industry uses LNPs as a leading non-viral delivery technology due to scalability, manufacturability, and adaptable formulation design. Manufacturing processes require precise control of particle size, encapsulation efficiency, surface charge, and stability, with microfluidic mixing often used to ensure reproducibility. Regulatory evaluation focuses on critical quality attributes, impurities, and consistent performance across batches. Safety considerations include immunostimulation, infusion reactions, and tissue distribution profiles. As gene therapies, RNA therapeutics, and personalised vaccines expand, LNP technology continues advancing through improved targeting, reduced toxicity, and enhanced endosomal escape, positioning it as a cornerstone delivery platform enabling next-generation genetic medicines.

Lipidation refers to the covalent attachment of lipid groups to proteins or peptides, altering their physicochemical properties, localisation, and biological behaviour. This modification can occur naturally as a post-translational event, or it can be engineered intentionally to enhance therapeutic performance. Lipidation often increases hydrophobicity and promotes association with cell membranes or carrier proteins, influencing distribution, stability, and half-life. Common lipid modifications include palmitoylation, myristoylation, and engineered fatty acid conjugation.

The biopharmaceutical industry uses lipidation strategically to improve pharmacokinetics and enable less frequent dosing for peptide and protein therapeutics. Lipidated peptides can bind serum albumin, reducing renal clearance and prolonging circulation time, thereby improving patient convenience and adherence. Manufacturing requires careful control to ensure consistent conjugation patterns, as lipid heterogeneity can affect potency, stability, and immunogenicity. Analytical characterisation typically includes mass spectrometry, chromatography, and bioactivity assays to confirm modification integrity and functional impact. As biologic modalities expand, lipidation remains a powerful formulation and design approach that enhances therapeutic durability without altering core biological mechanisms.

Liposome denotes a spherical vesicle composed of one or more phospholipid bilayers capable of encapsulating both hydrophilic and hydrophobic substances. These structures mimic natural cell membranes, enabling them to interact favourably with biological systems while protecting payloads from degradation. Liposomes vary in size, lamellarity, and surface properties, with formulations designed for controlled release, improved stability, and enhanced tissue delivery.

The pharmaceutical industry employs liposomal formulations to improve therapeutic index by enhancing delivery to target tissues while reducing systemic toxicity. Liposomes are particularly valuable for cytotoxic oncology agents, antifungal therapies, and vaccines, where controlled distribution and reduced off-target exposure are clinically meaningful. Surface modification strategies such as PEGylation improve circulation time, while ligand-based targeting enhances uptake in specific tissues or tumour microenvironments. Manufacturing requires tight control of particle size distribution, encapsulation efficiency, sterility, and stability. As nanomedicine advances, liposomes remain one of the most established and clinically validated delivery platforms translating membrane science into improved patient outcomes.

Liquid Biopsy refers to minimally invasive testing of circulating biomarkers in bodily fluids, most commonly blood, to detect or monitor disease. In oncology, liquid biopsy typically measures circulating tumour DNA, circulating tumour cells, or other molecular markers reflecting tumour burden, mutation status, and treatment response. Unlike tissue biopsy, liquid biopsy can be repeated over time, enabling dynamic monitoring of disease evolution, resistance mechanisms, and relapse risk.

The biopharmaceutical industry increasingly integrates liquid biopsy into clinical development and precision medicine strategies. Biomarker-driven trials use circulating tumour DNA to identify eligible patients, detect actionable mutations, and track response to targeted therapies. Liquid biopsy supports real-time monitoring of resistance mutations, enabling adaptive treatment strategies and improved clinical decision-making. Analytical challenges include low biomarker abundance, assay sensitivity, and standardisation across laboratories, requiring rigorous validation. Regulatory acceptance continues growing, particularly for companion diagnostics and monitoring applications, as evidence demonstrates clinical utility. Liquid biopsy represents a major shift towards personalised, longitudinal disease management.

Loading Dose refers to an initial higher dose of a drug administered to rapidly achieve therapeutic plasma concentrations, followed by maintenance doses to sustain steady-state levels. This strategy is commonly used when drugs have long half-lives or when immediate clinical effect is required, such as in acute infections, cardiac conditions, or seizure management. The loading dose is calculated based on target concentration, volume of distribution, and bioavailability.

The pharmaceutical industry designs loading dose strategies using pharmacokinetic modelling and clinical trial data to optimise early exposure without causing toxicity. Loading doses may be particularly relevant in biologics, monoclonal antibodies, or antiviral therapies where rapid target engagement improves outcomes. Clinical protocols must consider patient-specific factors such as renal function, body weight, and comorbidities that influence exposure. Regulatory labelling may include loading dose recommendations with safety monitoring guidance to prevent adverse effects associated with high initial concentrations. Proper loading dose design improves clinical response timelines and strengthens therapeutic consistency across diverse patient populations.

Local Tolerance describes the ability of a drug product to be administered at a specific site without causing unacceptable irritation, inflammation, pain, or tissue damage. This concept is particularly important for injectable, topical, inhaled, nasal, ophthalmic, and implantable therapies where formulation components directly contact sensitive tissues. Local tolerance issues may arise from pH extremes, excipient toxicity, high osmolality, particulate matter, or immune-mediated reactions.

The pharmaceutical industry evaluates local tolerance through preclinical studies, formulation screening, and clinical monitoring of injection site reactions or mucosal irritation. For biologics and vaccines, local reactions may include redness, swelling, induration, or delayed hypersensitivity, which must be characterised and managed through risk mitigation strategies. Device compatibility also influences local tolerance, particularly for autoinjectors and infusion systems where delivery mechanics affect tissue response. Regulatory submissions require clear documentation of local safety findings, including adverse event profiles and mitigation plans. Strong local tolerance improves patient adherence, supports long-term therapy use, and reduces discontinuation risk driven by administration discomfort.

LogP represents the partition coefficient of a compound between octanol and water, serving as a key indicator of lipophilicity and molecular distribution behaviour. It provides insight into how readily a molecule may cross biological membranes, dissolve in lipid environments, or remain in aqueous systems. LogP strongly influences drug absorption, permeability, tissue distribution, and metabolic stability, making it a central physicochemical parameter in early drug design.

The pharmaceutical industry uses LogP during lead optimisation to balance solubility and permeability, as excessive lipophilicity may reduce aqueous solubility and increase off-target binding or toxicity risks. Conversely, very low LogP can limit membrane permeability and reduce oral bioavailability. Medicinal chemists adjust LogP through structural modifications such as introducing polar groups, reducing aromaticity, or modifying ionisation properties. Regulatory expectations indirectly reflect LogP through formulation feasibility and bioavailability outcomes. As drug discovery increasingly focuses on complex targets, LogP remains a foundational metric supporting rational design of molecules that can achieve both biological potency and practical deliverability.

Long-Term Stability refers to the ability of a pharmaceutical product to maintain its quality, potency, purity, and performance over extended storage periods under defined conditions. Stability encompasses physical integrity, chemical stability, microbiological safety, and functional activity, particularly for biologics where degradation pathways include aggregation, deamidation, oxidation, and loss of bioactivity. Long-term stability studies generate data supporting shelf-life assignment, storage conditions, and packaging selection.

The biopharmaceutical industry conducts long-term stability programmes under ICH guidelines, using validated analytical methods to monitor critical quality attributes across time points. Biologics require particularly robust stability monitoring because small structural changes may affect safety or efficacy. Formulation development plays a major role in improving stability through buffer selection, stabilising excipients, and container closure optimisation. Regulatory submissions include stability protocols, trend analysis, and justification for proposed shelf-life, with ongoing stability commitments post-approval. Long-term stability directly impacts supply chain reliability, global distribution feasibility, and patient access, making it a core pillar of pharmaceutical quality assurance and lifecycle management.

Lyophilisation, also known as freeze-drying, is a preservation and stabilisation process that removes water from frozen materials by sublimation and desorption, producing a dry, porous product with preserved structure and activity. The process typically involves three stages: freezing, primary drying where ice sublimes under reduced pressure, and secondary drying where residual bound moisture is removed. Lyophilised products are highly stable, reconstitute efficiently, and are suitable for long-term storage.

The biopharmaceutical industry uses lyophilisation extensively for vaccines, monoclonal antibodies, peptides, enzymes, and injectable formulations that are unstable in liquid form. Cycle development requires careful optimisation of temperature and pressure profiles to prevent product collapse, ensure consistent cake structure, and maintain potency. Formulation design includes cryoprotectants and lyoprotectants such as sugars that stabilise proteins during freezing and drying. Regulatory expectations require validated lyophilisation processes, robust in-process controls, and stability data demonstrating shelf-life and reconstitution performance. As biologic complexity grows and global distribution needs increase, lyophilisation remains a critical technology enabling stable, transportable, and clinically reliable therapeutic products.

Lyophilise describes the process of removing water from a frozen material through sublimation under reduced pressure, producing a dry, porous product that retains structural and functional integrity. The term refers to the act of subjecting a material to freeze-drying conditions controlled to preserve biological activity and molecular structure throughout the drying process.

In pharmaceuticals, biologicals such as vaccines, proteins, and injectables are lyophilised to enhance shelf life, stability, and transportability. Lyophilised products reconstitute rapidly while maintaining biological activity. The process minimises thermal and chemical degradation compared to conventional drying approaches. Lyophilisation requires precise control of freezing rate, chamber pressure, and temperature profiles. Improper lyophilisation can lead to product collapse, loss of potency, or instability. The ability to lyophilise sensitive therapeutics enables global distribution of complex biologics and supports long-term storage of critical medical products across diverse supply chain environments.

Lysate refers to the fluid containing cellular contents released after cell lysis, including proteins, nucleic acids, metabolites, and organelle components. Lysates can be derived from bacterial, yeast, mammalian, or tissue samples, and they serve as essential materials for biochemical assays, protein purification, and molecular analysis. The lysis process may be mechanical, chemical, enzymatic, or thermal, with method selection influencing yield, integrity, and downstream compatibility.

The pharmaceutical and biotechnology industry uses lysates across research, manufacturing, and quality control workflows. In drug discovery, lysates enable target identification, enzyme activity assays, and Western blot analysis for pathway confirmation. In biologics manufacturing, cell lysates may be generated during downstream processing, requiring effective clarification and impurity removal strategies. Lysate-based systems also support cell-free expression technologies and rapid prototyping in synthetic biology. Quality considerations include protease activity, nucleic acid contamination, and batch-to-batch variability, requiring standardised protocols and stabilisation measures. Lysates remain a foundational tool linking cellular biology with analytical measurement across complex biological systems.

Macrophage designates a specialised phagocytic immune cell derived from circulating monocytes that infiltrates tissues throughout the body, performing critical functions in innate immunity, tissue homeostasis, inflammation resolution, and adaptive immune responses through pathogen clearance, antigen presentation, cytokine secretion, and wound healing coordination. These versatile cells exhibit remarkable plasticity, polarising into distinct functional phenotypes, with classically activated M1 macrophages producing pro-inflammatory mediators supporting pathogen elimination and tumour suppression, while alternatively activated M2 macrophages promote tissue repair, angiogenesis, and immune regulation.

The biopharmaceutical industry increasingly recognises macrophages as critical therapeutic targets and drug delivery vehicles given their central roles in cancer, autoimmune disorders, infectious diseases, atherosclerosis, and neurodegenerative conditions. Cancer immunotherapy strategies target macrophage biology through checkpoint inhibitors blocking CD47-SIRP? interactions, CSF-1R antagonists depleting tumour-associated macrophages, and bispecific antibodies engaging macrophage Fc receptors. Autoimmune disease therapies modulate macrophage activation reducing inflammatory cytokine production. Drug delivery exploits macrophage phagocytic capacity and tissue distribution, with nanoparticle formulations specifically targeting macrophages for treating infections, inflammatory diseases, or cancer metastases. As single-cell technologies reveal macrophage heterogeneity and spatial transcriptomics map macrophage localisation within diseased tissues, macrophage-targeted therapeutics continue advancing across oncology, immunology, and regenerative medicine.